Roland Selig

Tuebingen, BW 72072, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.

Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor.

Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor.

Journal: Journal of medicinal chemistry

Published: July 11, 2025

A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors.

A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 22, 2025

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example.

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example.

Journal: Journal of medicinal chemistry

Published: December 16, 2024

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 20, 2024

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.

Journal: Cell

Published: May 23, 2023

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.

Journal: European journal of medicinal chemistry

Published: April 13, 2022

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.

Journal: European journal of medicinal chemistry

Published: October 22, 2020

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).

Journal: European journal of medicinal chemistry

Published: July 24, 2020

Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.

Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.

Journal: European journal of medicinal chemistry

Published: July 21, 2020

A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.

A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.

Journal: Journal of medicinal chemistry

Published: September 07, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026